Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study

References

• Casasnovas RO, Haioun C, Dumontet C, et al. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin’s lymphomas. Groupe d’Etude des Lymphomes de l’Adulte. Haematologica. 2000;85:502–507.
   PubMed Web of Science ®Google Scholar
• Goss P, Stewart AK, Couture F, et al. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 1999;34:295–304.
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Heinz R, Pfeilstocker M, et al. Paclitaxel in the salvage treatment of Hodgkin’s disease and non-Hodgkin’s lymphoma. Ann Oncol. 1996;7:423–424.
   PubMed Web of Science ®Google Scholar
• Press OW, LeBlanc M, O'Rourke TJ, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. JCO. 1998;16:574–578.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. JCO. 1995;13:381–386.
   PubMed Web of Science ®Google Scholar
• Younes A, Ayoub JP, Sarris A, et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997;96:328–332.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Sand GJ, McGaughey D, et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004;100:2408–2414.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bailey HH, Smith EP, et al. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005;23:13–18.
   PubMed Web of Science ®Google Scholar
• Budman DR, Petroni GR, Johnson JL, et al. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. JCO. 1997;15:3275–3279.
   PubMed Web of Science ®Google Scholar
• Zekri JM, Hough RE, Davies JM, et al. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. Br J Cancer. 2003;88:1335–1338.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14:4200–4205.
   PubMed Web of Science ®Google Scholar
• Celgene. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Summit (NJ): Package Insert; 2015.
   Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11:231–246.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59–64.
   PubMed Web of Science ®Google Scholar
• Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol. 2011;6:998–1005.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Seitz J, Smetanay K, et al. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res. 2014;34:6609–6615.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–4554.
   PubMed Web of Science ®Google Scholar
• Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63:8226–8232.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood. 2011;117:3596–3608.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135:54–61.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. JCO. 2005;23:7794–7803.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. JCO. 2012;30:2055–2062.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Pro B, Hagemeister FB, McLaughlin P, et al. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:1818–1821.
   PubMed Web of Science ®Google Scholar
• Sinha R, Shenoy PJ, King N, et al. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:657–663.
   PubMed Web of Science ®Google Scholar
• Westin JR, McLaughlin P, Romaguera J, et al. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014;167:177–184.
   PubMed Web of Science ®Google Scholar
• Wang L, Xia ZJ. Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. Leuk Lymphoma. 2013;54:2553–2555.
   PubMed Web of Science ®Google Scholar
• Haritunians T, Mori A, O'Kelly J, et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007;21:333–339.
   PubMed Web of Science ®Google Scholar
• Chiang CT, Yeh PY, Gao M, et al. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett. 2010;298:195–203.
   PubMed Web of Science ®Google Scholar
• Danoch H, Kalechman Y, Albeck M, et al. Sensitizing B- and T- cell lymphoma cells to paclitaxel/abraxane-induced death by AS101 via inhibition of the VLA-4-IL10-survivin axis. Mol Cancer Res. 2015;13:411–422.
   PubMed Web of Science ®Google Scholar